Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 1.2× sales vs its 0.6× historical median P/S.
Fair value ≈ $3.32 · price $6.00 today
Overvalued · 81% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CMPD $13.50 $3.15 SELL/ TAKE PROFIT ON 10% AS PARTIAL SELL TO REDUCE COST TO ZERO ... from DAC (dollar average cost) (2) $3.18.
CHANGE EXIT TO $22.00 long term
https://stocktwits.com/G101SPM/message/618661000
UPDATE: FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data
CNPV awarded for COMP360 in TRD, further accelerating momentum
26-week (Part B) data from COMP006, expected in early Q3 2026
Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year
Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028
$CMPD $AGILQ $MRVL 🔥 MYNZ PR OUT 🚨 MarketBeat $120 PT (+3,000%) + Jonestrading $440 PT (+12,000%) Here is why:
🔥 NEWS: Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
DGX to distribute NextGen nationwide (18-mo option), $8M to fast-track FDA, TMO co-developing mRNA-based CRC screening. Supporters: P. Starke, G. Starke, F. Muniz. Low float, $50 soon! 🔥
I found you a MACD Bearish Reversal Divergence on the daily chart of CompuMed Inc. $CMPD #CMPD #macd #divergence #pink #tradingsignals #technicalanalysis
$CMPD CompuMed Integrates the Techcyte Digital Pathology Reviewing Platform to Help Increase Transplanted Organs
https://www.stocktitan.net/news/CMPD/compu-med-integrates-the-techcyte-digital-pathology-reviewing-zduby4im7jqv.html
$CMPD [15s. delayed]: Issued Press Release on June 12, 16:30:00: CompuMed Announces Purchase of Shares held by VI Capital and Changes in t https://s.flashalert.me/SJx6j6
$CMPD CompuMed Announces Purchase of Shares held by VI Capital and Changes in the Board of Directors
https://www.stocktitan.net/news/CMPD/compu-med-announces-purchase-of-shares-held-by-vi-capital-and-01w5xdv72o4b.html
$CMPD [15s. delayed]: Issued Press Release on May 25, 17:35:00: CompuMed Announces Approval and Amendment to Reduce Authorized Shares https://s.flashalert.me/UgSlo
$CMPD [15s. delayed]: Issued Press Release on March 22, 11:00:00: CompuMed CEO Lee Keddie Joins The Alliance National Innovation Leadershi https://s.flashalert.me/UlrlW
$CMPD CompuMed CEO Lee Keddie Joins The Alliance National Innovation Leadership Council
https://www.stocktitan.net/news/CMPD/compu-med-ceo-lee-keddie-joins-the-alliance-national-innovation-fnrylkvx2azn.html
$CMPD [15s. delayed]: Issued Press Release on December 27, 17:00:00: Compumed, Inc. Announces Fiscal 2022 Annual and Fourth Quarter Result https://s.flashalert.me/ZnMCw
$CMPD CompuMed, Inc. Announces Fiscal 2022 Third Quarter Results
https://www.stocktitan.net/news/CMPD/compu-med-inc-announces-fiscal-2022-third-quarter-gw0tzlzweqsf.html
